Pyramid Biosciences and GeneQuantum Healthcare Announce Preclinical Data for GQ1010, a Potential Best-In-Class TROP2-Targeted Antibody Drug Conjugate, at the 2023 AACR Annual Meeting

GQ1010 demonstrated greater tumor growth inhibition and more potent cytotoxicity than DS-1062 across several preclinical models GQ1010 in combination with anti-PD1 also showed synergistic in vivo tumor growth inhibition superior to DS-1062 plus anti-PD1 Differentiated preclinical safety…